Related Experiment Video
Updated: Nov 26, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?
1From the Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
Abstract:
The initial treatment regimens for advanced non-small cell lung cancer (NSCLC) have drastically evolved over the last 15 years with the rapid development of improved genomic sequencing technologies and the emergence of immune checkpoint inhibitors. Highly active oral kinase inhibitors are now approved for several molecularly defined subsets of NSCLC, including those harboring alterations in the EGFR, ALK, ROS1, BRAF, MET, RET, and NTRK genes, although acquired resistance to these targeted therapies remains a significant clinical challenge. In lung cancers lacking targetable mutations, programmed death 1/programmed death ligand 1 immune checkpoint inhibitors, used alone or in combination with cytotoxic T-lymphocyte-associated protein 4 inhibitors and/or cytotoxic chemotherapy, have led to meaningful improvements in overall survival. With many therapeutic options available to patients, here we review the recommended frontline treatment regimens for advanced NSCLC with and without targetable genomic drivers.
Insights
Advanced non-small cell lung cancer (NSCLC) treatment has evolved with targeted therapies for specific mutations and immune checkpoint inhibitors for other cases. This review covers frontline regimens for advanced NSCLC with or without targetable genomic drivers.
Area of Science:
- Oncology
- Genomics
- Immunotherapy
Background:
- Advanced non-small cell lung cancer (NSCLC) treatment has rapidly evolved.
- Genomic sequencing and immune checkpoint inhibitors have transformed therapeutic strategies.
- Targeted therapies and immunotherapies offer new hope for patients.
Purpose of the Study:
- To review current frontline treatment regimens for advanced NSCLC.
- To discuss treatment approaches for NSCLC with and without targetable genomic drivers.
- To highlight the impact of recent therapeutic advancements.
Main Methods:
- Review of current clinical guidelines and landmark studies.
- Analysis of data on targeted therapies and immune checkpoint inhibitors.
- Synthesis of evidence for frontline treatment selection.
Main Results:
- Targeted kinase inhibitors are approved for NSCLC with specific genetic alterations (EGFR, ALK, ROS1, BRAF, MET, RET, NTRK).
- Acquired resistance to targeted therapies remains a clinical challenge.
- Immune checkpoint inhibitors (PD-1/PD-L1), alone or combined with CTLA-4 inhibitors and/or chemotherapy, improve survival in NSCLC lacking targetable mutations.
Conclusions:
- Frontline treatment for advanced NSCLC depends on the presence of targetable genomic drivers.
- A combination of targeted therapies and immunotherapies represents a significant advancement in NSCLC care.
- Personalized treatment strategies based on molecular profiling are crucial for optimizing patient outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...